U.S. markets closed
  • S&P Futures

    4,168.00
    -23.50 (-0.56%)
     
  • Dow Futures

    34,105.00
    +8.00 (+0.02%)
     
  • Nasdaq Futures

    12,643.75
    -203.00 (-1.58%)
     
  • Russell 2000 Futures

    2,006.20
    -1.70 (-0.08%)
     
  • Crude Oil

    75.87
    -0.01 (-0.01%)
     
  • Gold

    1,929.80
    -1.00 (-0.05%)
     
  • Silver

    23.60
    -0.01 (-0.04%)
     
  • EUR/USD

    1.0898
    -0.0013 (-0.12%)
     
  • 10-Yr Bond

    3.3960
    -0.0010 (-0.03%)
     
  • Vix

    18.73
    +0.86 (+4.81%)
     
  • GBP/USD

    1.2213
    -0.0016 (-0.13%)
     
  • USD/JPY

    128.5690
    -0.0350 (-0.03%)
     
  • BTC-USD

    23,535.42
    -380.34 (-1.59%)
     
  • CMC Crypto 200

    536.29
    -9.02 (-1.65%)
     
  • FTSE 100

    7,820.16
    +59.05 (+0.76%)
     
  • Nikkei 225

    27,512.82
    +110.77 (+0.40%)
     

Bio-Path Holdings to Announce Third Quarter 2022 Financial Results on November 15, 2022

Bio-Path Holdings, Inc.
Bio-Path Holdings, Inc.

HOUSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Tuesday, November 15, 2022 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2022 and to provide a business overview.

To access the live conference call, please call (833) 630-1956 (domestic) or (412) 317-1837 (international) at least five minutes prior to the start time. A live audio webcast of the call will also be available on the Presentations section of the Company’s website, www.biopathholdings.com. An archived webcast will be available on the Bio-Path website approximately two hours after the event.

About Bio-Path Holdings, Inc.

Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers and BP1001-A, a drug product modification of prexigebersen, has been cleared by the FDA and Phase 1 studies in solid tumors will commence in 2022. The Company’s second product BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia. In addition, an IND is expected to be filed for BP1003, a novel liposome-incorporated STAT3 antisense oligodeoxynucleotide developed by Bio-Path as a specific inhibitor of STAT3, in 2022 or first quarter 2023.

For more information, please visit the Company's website at http://www.biopathholdings.com.

Contact Information:
                        
Investors

Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com

Doug Morris
Investor Relations
Bio-Path Holdings, Inc.
832-742-1369